Erythroid hematologic improvement according to IWG 2006 criteria
| HI-E . | No. patients/N (%) . |
|---|---|
| Baseline transfusion dependence* | 133/214 (62) |
| TR† | 40/133 (30) |
| TI‡ | 23/214 (17) |
| HbR§ | 30/81 (37) |
| Overall HI-E response (TR or HbR) | 70/214 (33) |
| HI-E . | No. patients/N (%) . |
|---|---|
| Baseline transfusion dependence* | 133/214 (62) |
| TR† | 40/133 (30) |
| TI‡ | 23/214 (17) |
| HbR§ | 30/81 (37) |
| Overall HI-E response (TR or HbR) | 70/214 (33) |
HI-E indicates hematologic improvement–erythroid.
Transfusion dependence criteria: 4 units or more of RBC transfusions triggered by Hb values of 90 g/L or less during the 8 weeks immediately preceding first dose of lenalidomide.
TR: decrease from baseline 8-wk RBC transfusion requirement of 4 units or more during any 8-wk period after first dose of lenalidomide.
TI: absence of RBC transfusions during any 8-wk period after first dose of lenalidomide.
HbR: Hb increase of 15 g/L or more from baseline sustained for 8 wk or more.